{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"2.7","value":"1.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was the duration of time from first administration of study treatment to date of first documented progression or death from any cause. It was based on tumor assessments made according to the IWG criteria as assessed by the IRC. The progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.","dispersionType":"95% Confidence Interval","groups":[{"description":"Belinostat 1000 mg/m\\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.","id":"OG000","title":"Belinostat"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Dataset included participants who received at least 1 dose of belinostat and had a confirmed PTCL diagnosis.","reportingStatus":"POSTED","timeFrame":"24 months","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}